好看日韩在线视频免费,日本不卡一区二区三区,三级a全过程在线观看,亚洲精品国产9999久久久久

行業(yè)產(chǎn)品

  • 行業(yè)產(chǎn)品

賽默飛世爾科技(中國)有限公司


MEM 氨基酸溶液 (50X)

返回列表頁
參  考  價(jià)面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)

產(chǎn)品型號Gibco

品       牌

廠商性質(zhì)其他

所  在  地

聯(lián)系方式:查看聯(lián)系方式

更新時(shí)間:2023-05-11 21:02:43瀏覽次數(shù):158次

聯(lián)系我時(shí),請告知來自 環(huán)保在線

產(chǎn)品簡介

MEM 氨基酸溶液 (50X)

詳細(xì)介紹

Gibco™ MEM Amino Acids Solution is used as a growth supplement for cell culture medium, to increase cell growth and viability. Gibco™ MEM Amino Acids Solution is formulated to contain 50X the essential amino acids (except L-glutamine) found in the standard Minimum Essential Medium (MEM). The complete formulation is available.

Product Use
For in vitro diagnostic use.

Dual-site cGMP Manufacturing and Quality System
Gibco™ MEM Amino Acids Solution is manufactured at a cGMP compliant facility, located in Paisley, Scotland, UK. The facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 standard. For supply chain continuity, Life Technologies offers a comparable Gibco™ MEM Amino Acids Solution product made in our Grand Island facility (11130-051). This facility is registered with the FDA as a medical device manufacturer and is certified to the ISO 13485 and ISO 9001 standards.

在中國境內(nèi), 本產(chǎn)品于非臨床科研用途, 產(chǎn)品信息以中文為準(zhǔn)。 (In China territory, the product is for Research Use only in non-clinical unit, product information in Chinese shall prevail.)
For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.


感興趣的產(chǎn)品PRODUCTS YOU ARE INTERESTED IN

環(huán)保在線 設(shè)計(jì)制作,未經(jīng)允許翻錄必究 .? ? ? Copyright(C)?2021 http://www.niunang.cn,All rights reserved.

以上信息由企業(yè)自行提供,信息內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由相關(guān)企業(yè)負(fù)責(zé),環(huán)保在線對此不承擔(dān)任何保證責(zé)任。 溫馨提示:為規(guī)避購買風(fēng)險(xiǎn),建議您在購買產(chǎn)品前務(wù)必確認(rèn)供應(yīng)商資質(zhì)及產(chǎn)品質(zhì)量。

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗(yàn)證碼

收藏該商鋪

登錄 后再收藏

提示

您的留言已提交成功!我們將在第一時(shí)間回復(fù)您~
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |